{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:30:26Z","timestamp":1775122226105,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T00:00:00Z","timestamp":1522627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T00:00:00Z","timestamp":1522627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca (IT), FIRB 2012","award":["RBFR12SOQ1"],"award-info":[{"award-number":["RBFR12SOQ1"]}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG15232"],"award-info":[{"award-number":["IG15232"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10637-018-0590-0","type":"journal-article","created":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T01:57:30Z","timestamp":1522634250000},"page":"985-998","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations"],"prefix":"10.1007","volume":"36","author":[{"given":"Elisabetta","family":"Bigagli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Luceri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"De Angioletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Chegaev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Riganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Gazzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Saponara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Longini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Luceri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1799-4828","authenticated-orcid":false,"given":"Lorenzo","family":"Cinci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,2]]},"reference":[{"issue":"2","key":"590_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.cell.2009.04.056","volume":"138","author":"Q Wang","year":"2009","unstructured":"Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, J\u00e4nne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138(2):245\u2013256. https:\/\/doi.org\/10.1016\/j.cell.2009.04.056","journal-title":"Cell"},{"issue":"2","key":"590_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11912-017-0568-7","volume":"19","author":"M Nakazawa","year":"2017","unstructured":"Nakazawa M, Paller C, Kyprianou N (2017) Mechanism of therapeutic resistance in prostate cancer. Curr Oncol Rep 19(2):13. https:\/\/doi.org\/10.1007\/s11912-017-0568-7","journal-title":"Curr Oncol Rep"},{"key":"590_CR3","first-page":"100","volume":"2","author":"E Castro","year":"2014","unstructured":"Castro E, Romero N, Olmos D (2014) State of the art treatment in castration resistant prostate cancer. EMJ Oncol 2:100\u2013105 https:\/\/www.emjreviews.com\/oncology\/article\/re-state-art-treatment-castration-resistant-prostate-cancer-forward-past\/re-state-of-the-art-treatment-in-castration-resistant-prostate-cancer-forward-to-the-past-again\/","journal-title":"EMJ Oncol"},{"key":"590_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ncpuro1296","volume":"6","author":"WP Harris","year":"2009","unstructured":"Harris WP, Mostaghel EA, Nelson PS, Montgomery B (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6:76\u201385. https:\/\/doi.org\/10.1038\/ncpuro1296","journal-title":"Nat Clin Pract Urol"},{"issue":"5","key":"590_CR5","doi-asserted-by":"publisher","first-page":"686","DOI":"10.6004\/jnccn.2014.0072","volume":"12","author":"JL Mohler","year":"2014","unstructured":"Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M (2014) National Comprehensive Cancer Network. Prostate cancer, version 2.2014. J Natl Compr Cancer Netw 12(5):686\u2013718 http:\/\/www.jnccn.org\/content\/12\/5\/686.abstract?utm_source=TrendMD&utm_medium=cpc&utm_campaign=JNCCN_TrendMD_0","journal-title":"J Natl Compr Cancer Netw"},{"key":"590_CR6","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1158\/0008-5472.CAN-12-0783","volume":"72","author":"M Thadani-Mulero","year":"2012","unstructured":"Thadani-Mulero M, Nanus DM, Giannakakou P (2012) Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Res 72:4611\u20134615. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-0783","journal-title":"Cancer Res"},{"key":"590_CR7","doi-asserted-by":"publisher","first-page":"7992","DOI":"10.1158\/0008-5472.CAN-10-0585","volume":"70","author":"ML Zhu","year":"2010","unstructured":"Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N (2010) Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 70:7992\u20138002. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-0585","journal-title":"Cancer Res"},{"key":"590_CR8","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.ctrv.2015.08.002","volume":"41","author":"C Buttigliero","year":"2015","unstructured":"Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio M, Scagliotti GV (2015) Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat Rev 41:884\u2013892. https:\/\/doi.org\/10.1016\/j.ctrv.2015.08.002","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"590_CR9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1200\/JCO.1983.1.8.477","volume":"1","author":"FM Torti","year":"1983","unstructured":"Torti FM, Aston D, Lum BL, Kohler M, Williams R, Spaulding JT, Shortliffe L, Freiha FS (1983) Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol 1(8):477\u2013482. https:\/\/doi.org\/10.1200\/JCO.1983.1.8.477","journal-title":"J Clin Oncol"},{"issue":"4","key":"590_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1200\/JCO.1994.12.4.683","volume":"12","author":"A Sella","year":"1994","unstructured":"Sella A, Kilbourn R, Amato R, Bui C, Zukiwski AA, Ellerhorst J, Logothetis CJ (1994) Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12(4):683\u2013688. https:\/\/doi.org\/10.1200\/JCO.1994.12.4.683","journal-title":"J Clin Oncol"},{"issue":"42","key":"590_CR11","doi-asserted-by":"publisher","first-page":"18202","DOI":"10.1073\/pnas.1006965107","volume":"107","author":"A Das","year":"2010","unstructured":"Das A, Durrant D, Mitchell C, Mayton E, Hoke NN, Salloum FN, Park MA, Qureshi I, Lee R, Dent P, Kukreja RC (2010) Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci U S A 107(42):18202\u201318207. https:\/\/doi.org\/10.1073\/pnas.1006965107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"590_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/srep32062","volume":"6","author":"JS Shankaranarayanan","year":"2016","unstructured":"Shankaranarayanan JS, Kanwar JR, Al-Juhaishi AJ, Kanwar RK (2016) Doxorubicin conjugated to immunomodulatory anticancer Lactoferrin displays improved cytotoxicity overcoming prostate Cancer chemo resistance and inhibits tumour development in TRAMP mice. Sci Rep 6:32062. https:\/\/doi.org\/10.1038\/srep32062","journal-title":"Sci Rep"},{"issue":"1","key":"590_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1021\/mp300311b","volume":"10","author":"C Riganti","year":"2013","unstructured":"Riganti C, Rolando B, Kopecka J, Campia I, Chegaev K, Lazzarato L, Federico A, Fruttero R, Ghigo D (2013) Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance. Mol Pharm 10(1):161\u2013174. https:\/\/doi.org\/10.1021\/mp300311b","journal-title":"Mol Pharm"},{"issue":"7","key":"590_CR14","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1021\/ml100302t","volume":"2","author":"K Chegaev","year":"2011","unstructured":"Chegaev K, Riganti C, Lazzarato L, Rolando B, Guglielmo S, Campia I, Fruttero R, Bosia A, Gasco A (2011) Nitric oxide donor \u2013 doxorubicin conjugates accumulate into doxorubicin resistant human colon cancer cells inducing cytotoxicity. ACS Med Chem Lett 2(7):494\u2013497. https:\/\/doi.org\/10.1021\/ml100302t","journal-title":"ACS Med Chem Lett"},{"issue":"5","key":"590_CR15","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.bmc.2016.01.021","volume":"24","author":"E Gazzano","year":"2016","unstructured":"Gazzano E, Chegaev K, Rolando B, Blangetti M, Annaratone L, Ghigo D, Fruttero R, Riganti C (2016) Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins. Bioorg Med Chem 24(5):967\u2013975. https:\/\/doi.org\/10.1016\/j.bmc.2016.01.021","journal-title":"Bioorg Med Chem"},{"issue":"10","key":"590_CR16","doi-asserted-by":"publisher","first-page":"4881","DOI":"10.1021\/acs.jmedchem.6b00184","volume":"59","author":"K Chegaev","year":"2016","unstructured":"Chegaev K, Rolando B, Cortese D, Gazzano E, Buondonno I, Lazzarato L, Fanelli M, Hattinger CM, Serra M, Riganti C, Fruttero R, Ghigo D, Gasco A (2016) H2S-donating Doxorubicins may overcome cardiotoxicity and multidrug resistance. J Med Chem 59(10):4881\u20134889. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00184","journal-title":"J Med Chem"},{"issue":"9","key":"590_CR17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nrd4623","volume":"14","author":"JO Lundberg","year":"2015","unstructured":"Lundberg JO, Gladwin MT, Weitzberg E (2015) Strategies to increase nitric oxide signalling in cardiovascular disease. Nat Rev Drug Discov 14(9):623\u2013641. https:\/\/doi.org\/10.1038\/nrd4623","journal-title":"Nat Rev Drug Discov"},{"key":"590_CR18","doi-asserted-by":"publisher","first-page":"925167","DOI":"10.1155\/2015\/925167","volume":"2015","author":"Y Shen","year":"2015","unstructured":"Shen Y, Shen Z, Luo S, Guo W, Zhu YZ (2015) The Cardioprotective effects of hydrogen sulfide in heart diseases: from molecular mechanisms to therapeutic potential. Oxidative Med Cell Longev 2015:925167\u2013925113. https:\/\/doi.org\/10.1155\/2015\/925167","journal-title":"Oxidative Med Cell Longev"},{"issue":"2","key":"590_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56(2):185\u2013229. https:\/\/doi.org\/10.1124\/pr.56.2.6","journal-title":"Pharmacol Rev"},{"issue":"11","key":"590_CR20","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","volume":"18","author":"S Zhang","year":"2012","unstructured":"Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18(11):1639\u20131642. https:\/\/doi.org\/10.1038\/nm.2919","journal-title":"Nat Med"},{"issue":"2","key":"590_CR21","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.etap.2014.07.016","volume":"38","author":"Charng Choon Wong","year":"2014","unstructured":"Wong CC, Sagineedu SR, Sumon SH, Sidik SM, Phillips R, Lajis NH, Stanslas J. NCI in vitro and in silico anticancer screen, cell cycle pertubation and apoptosis-inducing potential of new acylated, benzylidene and isopropylidene derivatives of andrographolide. Environ Toxicol Pharmacol 38(2):489\u2013501. https:\/\/doi.org\/10.1016\/j.etap.2014.07.016","journal-title":"Environmental Toxicology and Pharmacology"},{"issue":"2","key":"590_CR22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1158\/0008-5472.516.65.2","volume":"65","author":"C Riganti","year":"2005","unstructured":"Riganti C, Miraglia E, Viarisio D, Costamagna C, Pescarmona G, Ghigo D, Bosia A (2005) Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res 65(2):516\u2013525 http:\/\/cancerres.aacrjournals.org\/content\/65\/2\/516.long","journal-title":"Cancer Res"},{"key":"590_CR23","first-page":"1301","volume":"57","author":"HS Samaha","year":"1997","unstructured":"Samaha HS, Kelloff GJ, Steele V, Rao CV, Reddy BS (1997) Modulation of apoptosis by Sulindac, curcumin, Phenylethyl-3-methylcaffeate, and 6-Phenyihexyl Isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res 57:1301\u20131305 http:\/\/cancerres.aacrjournals.org\/content\/57\/7\/1301.long","journal-title":"Cancer Res"},{"issue":"6","key":"590_CR24","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/cam4.694","volume":"5","author":"L Cinci","year":"2016","unstructured":"Cinci L, Luceri C, Bigagli E, Carboni I, Paccosi S, Parenti A, Guasti D, Coronnello M (2016) Development and characterization of an in vitro model of colorectal adenocarcinoma with MDR phenotype. Cancer Med 5(6):1279\u20131291. https:\/\/doi.org\/10.1002\/cam4.694","journal-title":"Cancer Med"},{"issue":"9","key":"590_CR25","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0006-2952(98)00229-9","volume":"1;56","author":"LG Baggetto","year":"1998","unstructured":"Baggetto LG, Dong M, Bernaud J, Espinosa L, Rigal D, Bonvallet R, Marthinet E (1998) In vitro and in vivo reversal of cancer cell multidrug resistance by the semi-synthetic antibiotic tiamulin. Biochem Pharmacol 1;56(9):1219\u20131228 https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006295298002299?via%3Dihub","journal-title":"Biochem Pharmacol"},{"key":"590_CR26","first-page":"4243","volume":"47","author":"G Alessandri","year":"1987","unstructured":"Alessandri G, Filippeschi S, Sinibaldi P, Mornet F, Passera P, Spreafico F, Cappa PM, Gullino PM (1987) Influence of gangliosides on primary and metastatic neoplastic growth in human and murine cells. Cancer Res 47:4243\u20134247 http:\/\/cancerres.aacrjournals.org\/content\/47\/16\/4243.long","journal-title":"Cancer Res"},{"issue":"1","key":"590_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/4.1.23","volume":"4","author":"CWM Adams","year":"1956","unstructured":"Adams CWM (1956) A stricter interpretation of the ferric ferricyanide reaction with particular reference to the demonstration of protein-bound sulphydryl and di-sulphide. J Histochem Cytochem 4(1):23\u201335. https:\/\/doi.org\/10.1177\/4.1.23","journal-title":"J Histochem Cytochem"},{"key":"590_CR28","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ctrv.2008.05.004","volume":"34","author":"R Petrioli","year":"2008","unstructured":"Petrioli R, Fiaschi AI, Francini E, Pascucci A, Francini G (2008) The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer. Cancer Treat Rev 34:710\u2013718. https:\/\/doi.org\/10.1016\/j.ctrv.2008.05.004","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"590_CR29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S1078-1439(99)00055-1","volume":"5","author":"G Bhangal","year":"2000","unstructured":"Bhangal G, Halford S, Wang J, Roylance R, Shah R, Waxman J (2000) Expression of the multidrug resistance gene in human prostate cancer. Urol Oncol 5(3):118\u2013121 https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1078143999000551?via%3Dihub","journal-title":"Urol Oncol"},{"key":"590_CR30","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1042\/bse0500161","volume":"50","author":"FJ Sharom","year":"2011","unstructured":"Sharom FJ (2011) Multidrug resistance protein (P-glycoprotein; MDR1). Biochemical Society Essays Biochem 50:161\u2013178 https:\/\/pdfs.semanticscholar.org\/d6eb\/ca84e778bbbd34fcaf069db9d54c65f99c9b.pdf","journal-title":"Biochemical Society Essays Biochem"},{"issue":"38","key":"590_CR31","doi-asserted-by":"publisher","first-page":"63857","DOI":"10.18632\/oncotarget.19148","volume":"8","author":"D Wu","year":"2017","unstructured":"Wu D, Liu L, Yan X, Wang C, Wang Y, Han K, Lin S, Gan Z, Min D (2017) Pleiotrophin promotes chemoresistance to doxorubicin in osteosarcoma by upregulating P-glycoprotein. Oncotarget 8(38):63857\u201363870. https:\/\/doi.org\/10.18632\/oncotarget.19148","journal-title":"Oncotarget"},{"issue":"suppl 7","key":"590_CR32","doi-asserted-by":"publisher","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","volume":"23","author":"G. Curigliano","year":"2012","unstructured":"Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F, ESMO Guidelines Working Group (2012) Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol Suppl 7:155\u201366. https:\/\/doi.org\/10.1093\/annonc\/mds293","journal-title":"Annals of Oncology"},{"issue":"2","key":"590_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S (2016) A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7(2):27\u201331. https:\/\/doi.org\/10.4103\/0976-0105.177703","journal-title":"J Basic Clin Pharm"},{"key":"590_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-356","volume":"9","author":"KJ Patel","year":"2009","unstructured":"Patel KJ, Tannock IF (2009) The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. BMC Cancer 9:356. https:\/\/doi.org\/10.1186\/1471-2407-9-356","journal-title":"BMC Cancer"},{"issue":"3","key":"590_CR35","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1021\/acsmedchemlett.7b00016","volume":"8","author":"K Chegaev","year":"2017","unstructured":"Chegaev K, Fraix A, Gazzano E, Abd-Ellatef GE, Blangetti M, Rolando B, Conoci S, Riganti C, Fruttero R, Gasco A, Sortino S (2017) Light-regulated NO release as a novel strategy to overcome doxorubicin multidrug resistance. ACS Med Chem Lett 8(3):361\u2013365. https:\/\/doi.org\/10.1021\/acsmedchemlett.7b00016","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"590_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","volume":"31","author":"JV McGowan","year":"2017","unstructured":"McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM (2017) Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 31(1):63\u201375. https:\/\/doi.org\/10.1007\/s10557-016-6711-0","journal-title":"Cardiovasc Drugs Ther"},{"key":"590_CR37","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s00277-003-0615-3","volume":"82","author":"HW Auner","year":"2003","unstructured":"Auner HW, Tinchon C, Linkesch W, Tiran A, Quehenberger F, Link H, Sill H (2003) Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Haematol 82:218\u2013222. https:\/\/doi.org\/10.1007\/s00277-003-0615-3","journal-title":"Ann Haematol"},{"key":"590_CR38","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","volume":"109","author":"D Cardinale","year":"2004","unstructured":"Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circ 109:2749\u20132754. https:\/\/doi.org\/10.1161\/01.CIR.0000130926.51766.CC","journal-title":"Circ"},{"key":"590_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00277","volume":"4","author":"S Tian","year":"2014","unstructured":"Tian S, Hirshfield KM, Jabbour SK, Toppmeyer D, Haffty BG, Khan AJ, Goyal S (2014) Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients. Front Oncol 4:277. https:\/\/doi.org\/10.3389\/fonc.2014.00277","journal-title":"Front Oncol"},{"key":"590_CR40","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1056\/NEJM199809243391307","volume":"339","author":"PK Singal","year":"1998","unstructured":"Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900\u2013905. https:\/\/doi.org\/10.1056\/NEJM199809243391307","journal-title":"N Engl J Med"},{"issue":"1","key":"590_CR41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.yjmcc.2005.09.011","volume":"40","author":"SP Jones","year":"2006","unstructured":"Jones SP, Bolli R (2006) The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 40(1):16\u201323. https:\/\/doi.org\/10.1016\/j.yjmcc.2005.09.011","journal-title":"J Mol Cell Cardiol"},{"issue":"4","key":"590_CR42","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.niox.2012.03.006","volume":"26","author":"L Xi","year":"2012","unstructured":"Xi L, Zhu SG, Das A, Chen Q, Durrant D, Hobbs DC, Lesnefsky EJ, Kukreja RC (2012) Dietary inorganic nitrate alleviates doxorubicin cardiotoxicity: mechanisms and implications. Nitric Oxide 26(4):274\u2013284. https:\/\/doi.org\/10.1016\/j.niox.2012.03.006","journal-title":"Nitric Oxide"},{"issue":"21","key":"590_CR43","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.jacc.2011.01.024","volume":"57","author":"SG Zhu","year":"2011","unstructured":"Zhu SG, Kukreja RC, Das A, Chen Q, Lesnefsky EJ, Xi L (2011) Dietary nitrate supplementation protects against doxorubicin-induced cardiomyopathy by improving mitochondrial function. J Am Coll Cardiol 57(21):2181\u20132189. https:\/\/doi.org\/10.1016\/j.jacc.2011.01.024","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"590_CR44","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1253\/circj.CJ-08-0636","volume":"73","author":"YW Su","year":"2009","unstructured":"Su YW, Liang C, Jin HF, Tang XY, Han W, Chai LJ, Zhang CY, Geng B, Tang CS, Du JB (2009) Hydrogen sulfide regulates cardiac function and structure in adriamycin-induced cardiomyopathy. Circ J 73(4):741\u2013749 https:\/\/www.jstage.jst.go.jp\/article\/circj\/73\/4\/73_CJ-08-0636\/_article","journal-title":"Circ J"},{"issue":"46","key":"590_CR45","doi-asserted-by":"publisher","first-page":"17907","DOI":"10.1073\/pnas.0709010104","volume":"04","author":"DJ Lefer","year":"2007","unstructured":"Lefer DJ (2007) A new gaseous signaling molecule emerges: cardioprotective role of hydrogen sulfide. Proc Natl Acad Sci U S A 04(46):17907\u201317908. https:\/\/doi.org\/10.1073\/pnas.0709010104","journal-title":"Proc Natl Acad Sci U S A"},{"key":"590_CR46","doi-asserted-by":"publisher","first-page":"6841","DOI":"10.3892\/mmr.2015.4234","volume":"12","author":"MH Liu","year":"2015","unstructured":"Liu MH, Lin XL, Zhang Y, He J, Tan TP, Wu SJ, Liu J, Tian W, Chen L, Yu S, Li J, Yuan C (2015) Hydrogen sulfide attenuates doxorubicin-induced cardiotoxicity by inhibiting reactive oxygen species-activated extracellular signal-regulated kinase 1\/2 in H9c2 cardiac myocytes. Mol Med Rep 12:6841\u20136848. https:\/\/doi.org\/10.3892\/mmr.2015.4234","journal-title":"Mol Med Rep"},{"key":"590_CR47","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3892\/ijmm.2013.1246","volume":"31","author":"R Guo","year":"2013","unstructured":"Guo R, Lin J, Xu W, Shen N, Mo L, Zhang C, Feng J (2013) Hydrogen sulfide attenuates doxorubicin-induced cardiotoxicity by inhibition of the p38 MAPK pathway in H9c2 cells. Int J Mol Med 31:644\u2013650. https:\/\/doi.org\/10.3892\/ijmm.2013.1246","journal-title":"Int J Mol Med"},{"key":"590_CR48","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11010-011-1194-6","volume":"363","author":"XY Wang","year":"2012","unstructured":"Wang XY, Yang CT, Zheng DD, Mo LQ, Lan AP, Yang ZL, Hu F, Chen PX, Liao XX, Feng JQ (2012) Hydrogen sulfide protects H9c2 cells against doxorubicin-induced cardiotoxicity through inhibition of endoplasmic reticulum stress. Mol Cell Biochem 363:419\u2013426. https:\/\/doi.org\/10.1007\/s11010-011-1194-6","journal-title":"Mol Cell Biochem"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0590-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0590-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0590-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:25:38Z","timestamp":1678559138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0590-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,2]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["590"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0590-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,2]]},"assertion":[{"value":"9 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed. All animal care and experimental protocols were approved by the Italian Ministry of Health with authorization number 49\/2016-PR 21\/01\/2016.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}